GC
SGMO

Guggenheim Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Guggenheim Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-151,525
Closed -$2.57M – 2350
2018
Q3 		$2.57M Sell
151,525
-400
-0.3% -$6.08K 0.02% 1103
2018
Q2 		$2.16M Buy
151,925
+53,442
+54% +$888K 0.01% 1206
2018
Q1 		$1.87M Sell
98,483
-30,232
-23% -$646K ﹤0.01% 1688
2017
Q4 		$2.11M Buy
+128,715
New +$1.91M 0.01% 1631
2014
Q4 		– Sell
-209,263
Closed -$2.26M – 3092
2014
Q3 		$2.26M Buy
209,263
+34,059
+19% +$445K 0.01% 1675
2014
Q2 		$2.67M Sell
175,204
-7,336
-4% -$106K 0.01% 1570
2014
Q1 		$3.3M Sell
182,540
-15,994
-8% -$308K 0.01% 1395
2013
Q4 		$2.76M Buy
+198,534
New +$2.29M 0.01% 1498

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Guggenheim Capital's SGMO Position: Q4 2018 in Review

Guggenheim Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 151,525 shares — an estimated $2.57M sold.

Guggenheim Capital first reported a position in SGMO in Q4 2013 and held it in 8 quarters. The position peaked at $3.3M in Q1 2014. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • Guggenheim Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • Guggenheim Capital sold 151,525 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $2.57M.
  • Guggenheim Capital first reported a position in SANGAMO THERAPEUTICS INC in Q4 2013 and held it in 8 quarters.
  • Guggenheim Capital's SANGAMO THERAPEUTICS INC position peaked at $3.3M in Q1 2014.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on Guggenheim Capital's 13F filing for Q4 2018, filed 14 Feb 2019.